Audited Standalone & Consolidated Financial Results for the quarter and year ended on March 31, 2026
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.7 pts more than Nifty Microcap 250 and 6.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medicamen Biotech reported consolidated revenue of Rs. 20,088.29 Lacs for FY2026, up 19% from Rs. 16,879.10 Lacs in FY2025. The company achieved PAT growth of 49.5% to Rs. 979.64 Lacs (standalone: Rs. 940.87 Lacs, down marginally by 0.4%). Consolidated EPS improved to Rs. 7.22 from Rs. 5.16. The Board recommended a final dividend of Rs. 1 per equity share (10% face value). Auditors Rai Qimat & Associates issued an unmodified opinion with no going concern issues. The company raised equity capital of Rs. 5,356.79 Lacs through preferential issues and warrants during the year. Subsidiaries contributed significantly with combined revenue of Rs. 20,088.29 Lacs and assets of Rs. 37,198.84 Lacs.
Strong PAT growth of 49.5% on consolidated basis and 19% revenue growth indicate solid performance. Equity raise strengthens balance sheet. The stock could see positive reaction given robust profitability growth and clean audit.